Terbisil

Selected form

Terbinafine Hydrochloride

Method of action: Antifungal Broad Spectrum

Treatment option: Fungal Infection, Jock Itch, Infection, Athlete'S Foot

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Terbisil

Property	Description
Active ingredient	Terbinafine Hydrochloride
Form	Tablet, Cream, Solution, Spray
Pharmacological class	Allylamine Antifungal Agent
General purpose	Fungal infection clearance (Fungicidal)
Origin	Synthetic Compound

Terbinafine: Defining the Antifungal Agent and its Differentiation

Terbisil is a proprietary brand of the synthetic, single-ingredient medicine identified by its core active substance, Terbinafine Hydrochloride. This drug is available as a prescription-only agent for both oral (systemic) and topical (dermatological) routes. Terbinafine is classified as a potent allylamine antifungal agent, a designation that confirms its targeted design against certain fungal pathogens. The drug is characterized by its strong fungicidal action, meaning it is intended to kill the fungal cells directly, rather than merely inhibiting growth. The general purpose of Terbinafine is to achieve sustained eradication of fungal pathogens.

Mechanism Principle and Medical Recognition

The medication is formulated into several distinct dosage forms, including the tablet for oral preparation and various topical preparations such as cream and solution. The ability to use systemic or local delivery is a key distinguishing feature of its use profile. Terbinafine is recognized by medical authorities as a standard treatment for achieving mycological cure. This indicates that the active ingredient is a frequently utilized choice for clinical fungal management.

Terbinafine works by selectively targeting a crucial process within the fungal cell. Specifically, the active ingredient inhibits the enzyme squalene epoxidase. This mechanism leads to the accumulation of squalene and the depletion of ergosterol, compromising the fungal cell structure and resulting in its death.

What side effects are possible with Terbisil?

Possible Side Effects and Safety Information

The most common adverse reactions reported with Terbisil (oral terbinafine) are generally mild and temporary. However, the medication is associated with a risk of serious and potentially life-threatening side effects.

Common and Non-Serious Adverse Reactions

Side effects frequently reported in clinical studies include headache, gastrointestinal symptoms (such as diarrhea, nausea, abdominal pain, or dyspepsia), and skin reactions like rash and hives. Musculoskeletal reactions, including joint pain and muscle pain, are also commonly reported.

Serious and Clinically Significant Adverse Reactions

Hepatotoxicity and Liver Failure: Cases of severe liver injury, including liver failure requiring transplant or leading to death, have been reported in patients with and without pre-existing liver disease. Liver function tests are advised before treatment initiation. Terbisil is contraindicated in patients with chronic or active liver disease.
Taste and Smell Disturbances: Changes in the sense of taste (dysgeusia/loss of taste) and smell (anosmia/loss of smell) are documented. These disturbances can be severe, potentially resulting in decreased food intake, weight loss, and depressive symptoms, and may be permanent. Discontinuation is required if these symptoms occur.
Severe Skin Reactions: Serious conditions like Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have occurred. Any progressive skin rash must be reported immediately, and treatment should be discontinued.
Hematologic Effects: Rare cases of severe blood disorders, including neutropenia and thrombotic microangiopathy, have been reported. A complete blood count may be monitored, and treatment must be discontinued if the neutrophil count drops significantly.

Safety Restrictions and Monitoring

Terbisil is not recommended for use in patients with chronic or active liver disease. Pretreatment and subsequent monitoring of liver function is advised. Physicians should be alert to the development of depressive symptoms, and patients should be advised to report any signs of persistent nausea, vomiting, right upper abdominal pain, jaundice, or dark urine, as these may indicate liver injury and necessitate immediate discontinuation.

Overdose and Emergency Response

The official regulatory profile for Terbinafine describes specific manifestations that may occur in cases of acute overconsumption, including gastrointestinal effects such as nausea, vomiting, and epigastric pain, alongside neurological symptoms like headache and dizziness. Accidental ingestion of a topical formulation is systemically comparable to ingesting a half-dose oral tablet.

The profile strictly defines when urgent medical help is required. Patients must seek immediate medical attention for suspected overdose and must report immediately any symptoms suggesting severe toxicity. These high-risk signs include persistent nausea, loss of appetite, fatigue, right upper abdominal pain, or the presence of jaundice, dark urine, or pale stools.

Immediate drug discontinuation and medical evaluation are mandated upon the onset of a progressive skin rash, as this may signal life-threatening conditions such as Stevens-Johnson Syndrome (SJS) or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). The drug must also be discontinued if severe neutropenia is documented in blood counts.

Because no specific antidote is known, regulatory guidance centers on providing symptomatic and supportive treatment. Measures include attempting the elimination of the active substance, often starting with the administration of activated charcoal. Hospital monitoring is often required due to the documented risk of liver failure and other severe systemic outcomes.

Therapeutic Uses of Terbisil

What Terbisil Treats: Main Uses and Benefits

Terbisil (Terbinafine) is used for managing the fungal pathogens associated with skin, nail, and scalp infections. This medication is commonly used to help with conditions that present with systemic or localized discomfort caused by a persistent fungal presence.

This agent is relevant for managing symptom clusters that may become intense or disruptive, such as those associated with onychomycosis (nail fungus), Tinea Pedis (athlete's foot), Tinea Cruris (jock itch), Tinea Corporis (body ringworm), and Tinea Capitis (scalp ringworm). The key therapeutic benefit is that it supports general well-being during symptomatic phases by assisting with maintaining functional stability and supporting day-to-day comfort.

Quick Fact: Relief for Fungal Skin Symptoms

This medication is applied in addressing symptoms related to inflammatory or irritative states, such as the pronounced itching, scaling, and redness typical of Tinea infections.

Terbisil is commonly used across conditions presenting with acute episodes and recurrent or persistent manifestations. For fungal nail disease, it may be part of symptomatic management in conditions that affect the nail structure, and for children, it is considered relevant for easing symptoms of Tinea Capitis that interfere with daily functioning.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Terbisil?

Regulatory agencies define specific population rules for the use of Terbisil (Terbinafine tablets), primarily based on pre-existing conditions and age.

Absolute Non-Eligibility (Contraindications)

Terbisil is formally contraindicated and must not be used in individuals who have a known hypersensitivity to terbinafine or any component of the medicine. It is also absolutely prohibited for patients with chronic or active hepatic disease.

Classification	Population or Condition
Contraindicated	Active or Chronic Hepatic Disease
Contraindicated	Hypersensitivity to Terbinafine

Conditional and Restricted Use

Use is not recommended for patients with renal impairment where the creatinine clearance is less than 50 mL/min. The medicine should be used with caution in patients who have psoriasis or lupus erythematosus, as exacerbation of these conditions has been reported.

Age and Reproductive Status

Safety and efficacy have not been established for children younger than 4 years of age for the oral tablet formulation. For older adults, pre-existing hepatic or renal function must be assessed. The medicine is not recommended for breastfeeding mothers or for use during pregnancy, as the substance is excreted in breast milk and clinical experience during pregnancy is limited.

What should I know about interactions with other medicines?

Terbisil Interactions with other medicines and products

This section outlines the officially documented interaction patterns for oral Terbisil (Terbinafine) as specified in government regulatory documents.

Documented Metabolic Interactions

Oral Terbinafine is recognized by regulatory agencies as an inhibitor of the Cytochrome P450 2D6 (CYP2D6) enzyme. This inhibition can significantly reduce the clearance of other medicines primarily metabolized by CYP2D6, such as tricyclic antidepressants and certain beta-blockers. For example, co-administering Terbinafine with Desipramine is officially documented to increase Desipramine exposure substantially.

Conversely, other medicines can alter Terbinafine's exposure. The regulatory label notes that inhibitors of other CYP enzymes, such as Fluconazole or Cimetidine, can reduce Terbinafine's clearance, leading to higher systemic levels. Conversely, strong inducers, like Rifampin, can increase Terbinafine's clearance, potentially reducing its systemic exposure.

Other Significant Interactions

Interaction Partner (Agent Class)	Officially Documented Effect	Constraint/Note (from Label)
Warfarin (Anticoagulant)	Rare reports of altered International Normalized Ratio (INR).	Requires monitoring of prothrombin time.
Caffeine (Methylxanthine)	Clearance is officially decreased by Terbinafine.	N/A (Observed interaction)
Alcohol	Both Terbinafine and alcohol carry a risk of liver damage.	Potential for additive risk is noted.

Population-Specific Constraints

The oral form of Terbinafine is officially not recommended for patients diagnosed with chronic or active liver disease. This is a restriction tied to the drug’s metabolism and the increased risk documented in this population.

Mechanism of Action

Inhibition of Fungal Sterol Synthesis

This mechanism starts with the drug inhibiting the enzyme Squalene Epoxidase within the fungal cell. This molecular interaction directly blocks the essential Ergosterol biosynthesis pathway, which is necessary for the pathogen's survival and structural integrity.

Dual Cell Toxicity and Membrane Lysis

The enzyme blockade produces two immediate, critical consequences: the toxic build-up of the precursor Squalene and the resulting severe depletion of Ergosterol in the cell membrane. This structural and biochemical failure leads directly to the fungicidal effect, meaning the mechanism causes the fungal cell to die.

Mechanistic Selectivity for Pathogen Pathways

The drug's mechanism is highly selective, demonstrating activity against the fungal enzyme while showing a low inhibitory effect on the analogous enzyme in human cells responsible for cholesterol production. This specificity confines the mechanistic action to the target organism.

Dosage and Administration Information

How to Use Terbisil

The administration of Terbisil (Terbinafine) is defined by its approved routes and a standardized dosing protocol. The agent is available for oral administration (tablets and granules) for systemic effect, and for topical administration (creams, solutions, or sprays) for localized cutaneous infections.

For systemic use in adults, the standard regimen is fixed at 250 mg once daily. The total duration of this regimen is strictly dependent upon the infection site; for instance, the treatment course is generally six weeks for fingernail onychomycosis, extending to twelve weeks for toenail infections. Topical applications typically require shorter courses, often lasting between one and two weeks.

Official Administration Guidelines

Guideline	Official Instruction
Dosing Frequency	Administered once daily for all systemic uses.
Intake Condition	Oral tablets may be taken without regard to meals.
Pediatric Use	Oral dosing is determined by the patient's body weight, utilizing specific granule strengths.
Procedural Note	Granules must be administered with non-acidic food and swallowed immediately, not chewed.
Duration Timing	The final clinical effect is observed months after treatment cessation, corresponding to the time needed for the new, healthy nail to grow out.
High-Level Restriction	Standard protocols advise against use in patients with renal or hepatic impairment.

This structured approach ensures that the systemic administration follows a fixed frequency and dose, with the duration adjusted according to the specific infection type.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Terbisil

Evidence for use in Onychomycosis (Fungal Nail Disease)

The research foundation for Terbisil (Terbinafine) relies upon multiple Randomized Controlled Trials (RCTs) and subsequent systematic reviews, primarily comparing the oral tablet formulation against controls. Studies monitored fungal clearance endpoints and visible improvement endpoints which assessed the change in the visible appearance of the nail. Uncertainty remains regarding the full profile of long-term outcomes and durability of clearance, especially since research exploring certain special populations often relied on modest sample sizes.

Evidence for use in Tinea Infections (Athlete's Foot, Ringworm, and Jock Itch)

Research for tinea skin infections, including athlete's foot and ringworm, consists primarily of RCTs of topical formulations. These studies explored short-term symptom changes, monitoring fungal clearance alongside outcomes linked to inflammatory or irritative states such as itching and redness. Research typically used shorter follow-up durations, meaning there is limited information regarding long-term maintenance or observed patterns of recurrence.

Evidence for use in Tinea Capitis (Scalp Ringworm in Children)

Research examining Terbisil for Tinea Capitis was conducted predominantly within the pediatric population. The studies monitored fungal clearance endpoints and measured the functional outcome of hair regrowth. A key limitation is that findings often varied depending on the specific causative fungal species. Evidence for adult cases of Tinea Capitis is generally insufficient.

Long-Term Follow-up and Evidence Gaps

Extended observation studies were conducted to determine whether the clearance of fungal pathogens was associated with patterns of stability after the treatment interval concluded. Follow-up durations were limited in many initial trials, meaning long-term effects are not fully established for certain conditions. Additionally, while research has explored patients with comorbid conditions, sample sizes were modest in these specific cohorts, limiting the generalizability of findings.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Terbisil (FAQ)

Q: What is Terbisil and what is it used for?

Terbisil contains the active ingredient terbinafine, which is an antifungal medication. It is used to treat various fungal infections, particularly those caused by dermatophytes.

It is mainly indicated for:

Fungal infections of the nails (onychomycosis) in the fingers and toes.
Fungal infections of the scalp (Tinea capitis), primarily in children.
Widespread fungal infections of the skin that cannot be treated effectively with topical medication, such as ringworm (Tinea corporis), jock itch (Tinea cruris), and athlete's foot (Tinea pedis).

Q: How does Terbisil work?

Terbisil works by blocking an enzyme within the fungus called squalene epoxidase. This blockage prevents the fungus from producing ergosterol, a vital component of its cell membrane. The disruption of the cell membrane, combined with the buildup of squalene inside the fungal cell, ultimately kills the fungus or stops it from growing.

Q: What are the common side effects of Terbisil?

Common side effects that may occur with Terbisil include:

Headache
Gastrointestinal issues like nausea, diarrhea, abdominal pain, and indigestion (dyspepsia)
Rash or hives (urticaria)
Joint pain (arthralgia) or muscle pain (myalgia)
Changes in or loss of taste (dysgeusia or ageusia)

These side effects are usually mild to moderate and often lessen as treatment continues.

Q: Can Terbisil affect my liver?

Yes, Terbisil can potentially affect the liver. In rare cases, it has been associated with serious liver problems, including liver failure. Because of this risk, blood tests to check your liver function may be performed before you start taking Terbisil and possibly during treatment.

You should contact your healthcare provider immediately if you experience any signs of liver problems, such as:

Nausea or vomiting
Upper right-side stomach pain
Dark urine or pale stools
Yellowing of the skin or the whites of the eyes (jaundice)

Q: What should I tell my doctor before taking Terbisil?

It's important to discuss your full medical history and current health status with your doctor. Specifically, you should inform your doctor if you have, or have had, the following conditions:

Liver disease (acute or chronic)
Kidney problems
Blood disorders
Systemic lupus erythematosus (SLE)
A weakened immune system

Also, let your doctor know about all prescription and non-prescription medicines, supplements, and herbal products you are currently taking.

How should Terbisil be stored and disposed of?

Storage and Disposal Requirements

Terbisil (terbinafine) must be stored and handled according to specific regulatory guidelines to maintain its stability.

Item	Requirement Summary
Temperature	Tablets: Store at controlled room temperature, typically 20 C to 25 C. Topical forms: Store below 30 C.
Environmental Protection	The medicine must be protected from heat, moisture, direct light, and must not freeze (applies to all forms).
Packaging Rules	Tablets must be kept in the original package. Terbisil cream tubes must be kept tightly closed.
Stability	Terbisil cream has an official shelf life of 28 days after the tube is first opened, after which it must be discarded.
Child Safety	All forms must be kept out of the sight and reach of children.
Disposal	Do not throw away via wastewater or household waste. Dispose of unused product in accordance with local official requirements and seek guidance from a pharmacist.